A 24-month Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Efficacy Safety Tolerability Biomarker and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to determine if AZD3293 is effective and safe in treating early Alzheimer?s disease compared with placebo, and to determine if AZD3293 has an effect on biomarkers.
Description
The purpose of this study is to evaluate the potential of AZD3293 to be a disease-modifying treatment for early Alzheimer's disease by providing evidence of the compound's safety, tolerability, and impact on cognitive decline and on biomarkers relevant to AD in subjects with early AD.
Details
| Condition | Alzheimer's disease |
|---|---|
| Age | 55years - 85years |
| Clinical Study Identifier | TX6643 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.